UNIGE document Scientific Article
previous document  unige:107413  next document
add to browser collection

Haematological malignancies following temozolomide treatment for paediatric high-grade glioma

Karremann, Michael
Krämer, Nadja
Hoffmann, Marion
Wiese, Maria
Beilken, Andreas
Corbacioglu, Selim
Dilloo, Dagmar
Driever, Pablo Hernáiz
show hidden authors show all authors [1 - 14]
Published in European journal of cancer. 2017, vol. 81, p. 1-8
Abstract Temozolomide (TMZ) is widely used in high-grade glioma (HGG). There is a major concern of treatment-induced secondary haematological malignancies (SHMs). Due to the poor overall survival of HGG patients, the true incidence is yet elusive. Thus, the aim of this study was to determine the risk of SHMs following TMZ in paediatric HGG.
Keywords AdolescentAntineoplastic AgentsAlkylating/adverse effectsAustria/epidemiologyChildChildPreschoolDacarbazine/adverse effects/analogs & derivativesFemaleFollow-Up StudiesGermany/epidemiologyGlioma/drug therapyHematologic Neoplasms/chemically induced/epidemiologyHumansIncidenceInfantKaplan-Meier EstimateMaleSwitzerland/epidemiology
PMID: 28586748
Full text
Article (Published version) (637 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Oncologie et hématologie pédiatrique (907)
(ISO format)
KARREMANN, Michael et al. Haematological malignancies following temozolomide treatment for paediatric high-grade glioma. In: European Journal of Cancer, 2017, vol. 81, p. 1-8. doi: 10.1016/j.ejca.2017.04.023 https://archive-ouverte.unige.ch/unige:107413

291 hits

0 download


Deposited on : 2018-09-04

Export document
Format :
Citation style :